The Evolution of Prognostic Factors in Multiple Myeloma.
The Evolution of Prognostic Factors in Multiple Myeloma.
复制标题
DOI：
10.1155/2017/4812637
复制
发表时间：
2017
影响因子：
--
通讯作者：
Alsharif F
中科院分区：
文献类型：
--
作者：
Hanbali A;Hassanein M;Rasheed W;Aljurf M;Alsharif F
多发性骨髓瘤（MM）是一种异质性恶性血液病，涉及由不同遗传事件引起的浆细胞增殖，这些遗传事件有助于该疾病的发生、进展和预后。尽管在过去十年中MM的治疗策略有所改善，但该疾病仍然无法治愈。目前，所有的努力都集中在了解疾病的预后标志物，希望将新的治疗方式，将疾病转化为可治愈的。我们提出这一全面的审查，以总结目前的标准预后标记物在MM沿着新的技术，仍在开发中，并强调其在当前的临床实践的影响。
Multiple myeloma (MM) is a heterogeneous hematologic malignancy involving the proliferation of plasma cells derived by different genetic events contributing to the development, progression, and prognosis of this disease. Despite improvement in treatment strategies of MM over the last decade, the disease remains incurable. All efforts are currently focused on understanding the prognostic markers of the disease hoping to incorporate the new therapeutic modalities to convert the disease into curable one. We present this comprehensive review to summarize the current standard prognostic markers used in MM along with novel techniques that are still in development and highlight their implications in current clinical practice.